NCT04368455

Virtual Immersive Communication Training on Recommending Immunizations

Completed NA Results posted Last updated 12 April 2023

What this trial tests

NA trial testing Virtual Immersive Communication Training on Recommending Immunizations (VICTORI) in Human Papilloma Virus in 161 participants. Completed in 1 December 2022.

Timeline

23 June 2020

Primary endpoint
31 March 2021

1 December 2022

Quick facts

Lead sponsor	Brittany Rosen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	161
Start date	23 June 2020
Primary completion	31 March 2021
Estimated completion	1 December 2022
Sites	1 location across United States

Drugs / interventions tested

• Virtual Immersive Communication Training on Recommending Immunizations (VICTORI)
• HPV Same Way Same Day App

Conditions studied

• Human Papilloma Virus — all drugs for Human Papilloma Virus →

Sponsor

Brittany Rosen

Who can join

18 and older, any sex, with Human Papilloma Virus. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percent Change From Baseline in the Percentage of Participants With HPV Vaccine Initiation Primary · 6 months

The primary outcome was the percent change from pre versus post VICTORI in rates of HPV vaccine initiation among eligible patients presenting to clinic.

Group	Value	95% CI
Primary Care Clinic	18.1	11.0 – 25.8
Control Primary Care Clinic	3.9	-11.0 – 19.0

Physicians Perceived Barriers Secondary · 3 months

Physicians level barriers for recommendation of the HPV Vaccine following participation in VICTORI. Sum of 4 survey items using a 4 point scale (minimum score =4, maximum=16). A higher score indicates more barriers.

Pre-VICTORI

Group	Value	95% CI
Primary Care Clinic	7.39	± 1.67

Post-VICTORI

Group	Value	95% CI
Primary Care Clinic	6.87	± 1.66

3-Month Post- VICTORI

Group	Value	95% CI
Primary Care Clinic	6.75	± 1.59

Physicians Perceived Risk Secondary · 3 months

Physicians risk of HPV for their patients following participation in VICTORI. Sum of 5 survey items using a 3 point scale (minimum score =5, maximum=15). A higher score indicates higher perceived risk for patients.

Pre-VICTORI

Group	Value	95% CI
Primary Care Clinic	10.53	± 2.43

Post-VICTORI

Group	Value	95% CI
Primary Care Clinic	12.07	± 2.26

3 Month Post-VICTORI

Group	Value	95% CI
Primary Care Clinic	11.36	± 2.36

Physicians Attitudes Toward the HPV Vaccine Secondary · 3 months

Physicians attitudes toward the HPV vaccine following participation in VICTORI. Sum of 12 survey items using a 5 point scale (minimum score =12, maximum=60). A higher score indicates physician perception of increased importance towards the HPV vaccine.

Pre-VICTORI

Group	Value	95% CI
Primary Care Clinic	49.68	± 8.73

Post-VICTORI

Group	Value	95% CI
Primary Care Clinic	54.24	± 6.28

3-Month Post-VICTORI

Group	Value	95% CI
Primary Care Clinic	53.15	± 7.19

Physicians Strength of Recommendation of the HPV Vaccine Secondary · 3 months

Physicians strength of recommendation of the HPV vaccine following participation in VICTORI. Sum of 8 survey items using a 4 point scale (minimum score =8, maximum=32). A higher score indicates stronger recommendation of HPV vaccine.

Pre-VICTORI

Group	Value	95% CI
Primary Care Clinic	28.49	± 3.37

Post-VICTORI

Group	Value	95% CI
Primary Care Clinic	28.76	± 2.53

3-Month Post-VICTORI

Group	Value	95% CI
Primary Care Clinic	29.17	± 2.35

Physicians Self-efficacy Secondary · 3 months

Physicians self-efficacy for recommendation of the HPV Vaccine following participation in VICTORI. Sum of 5 survey items using a 5 point scale (minimum score =2, maximum=10). A higher score indicates higher self-efficacy.

Pre-VICTORI

Group	Value	95% CI
Primary Care Clinic- Physicians	7.44	± 1.27

Post- VICTORI

Group	Value	95% CI
Primary Care Clinic- Physicians	9.55	± 0.76

3-Month Post-VICTORI

Group	Value	95% CI
Primary Care Clinic- Physicians	9.27	± 0.88

Sponsor's own description

Our approach will be to implement Virtual Immersive Communication Training on Recommending Immunizations (VICTORI), an intervention that includes a self-directed app based curriculum and VR simulations, designed to increase the strength and consistency of HPV vaccine recommendations among clinicians. A single-site intervention assessing the efficacy of VICTORI in increasing HPV vaccine rates will be conducted.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Impact of a Virtual Reality Curriculum on Human Papillomavirus Vaccination: A Pilot Trial.
   Real FJ, Ollberding NJ, Meisman AR, DeBlasio DJ, et al · · 2022 · cited 12× · PMID 35778065 · DOI 10.1016/j.amepre.2022.05.003
2. Physicians' Human Papillomavirus Vaccine Communication With Parents of Different Skin Color: Feasibility of Measuring Indicators of Implicit Bias With Virtual Reality.
   Popler E, Rosen BL, Meisman AR, Lee MR, et al · · 2024 · cited 2× · PMID 38493391 · DOI 10.1016/j.jadohealth.2024.02.017